Rafferty Asset Management
INDV icon

Rafferty Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Rafferty Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
+5,215
New +$189K ﹤0.01% 1089
2026
Q1 		– Sell
-6,596
Closed -$237K – 1106
2025
Q4 		$237K Buy
+6,596
New +$201K ﹤0.01% 1049

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's INDV Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 5,215 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #1089 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in INDV as recently as Q4 2025.

Rafferty Asset Management first reported a position in INDV in Q4 2025 and has held it in 2 quarters since. The position peaked at $237K in Q4 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Rafferty Asset Management held 5,215 shares of Indivior Pharmaceuticals worth $214K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Rafferty Asset Management position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1089 holding.
  • Rafferty Asset Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Rafferty Asset Management's Indivior Pharmaceuticals position peaked at $237K in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.